Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -59.43%2.8M | 66.25%417.45K | -57.22%390.82K | 65.52%1.76M | -94.99%234.51K | -38.75%6.91M | -82.81%251.09K | -81.96%913.57K | -64.72%1.06M | 168.43%4.68M |
Operating revenue | -59.43%2.8M | -4.98%461.08K | -55.80%390.82K | 73.49%1.75M | -94.99%234.51K | -38.75%6.91M | -66.78%485.23K | -82.54%884.17K | -66.57%1.01M | 168.43%4.68M |
Cost of revenue | -52.53%3.02M | 10.32%592.34K | -54.70%460.97K | 60.49%1.58M | -89.84%388.88K | -37.18%6.37M | -59.01%536.92K | -77.21%1.02M | -63.63%985.02K | 131.53%3.83M |
Gross profit | -140.52%-219.62K | 38.81%-174.9K | 32.59%-70.15K | 128.48%179.8K | -118.09%-154.38K | -52.65%542.08K | -289.29%-285.83K | -117.43%-104.06K | -74.30%78.69K | 842.76%853.28K |
Operating expense | -15.53%2.95M | 19.74%849.5K | -3.77%676.52K | -16.13%657.01K | -40.79%769.43K | -43.97%3.5M | -50.50%709.47K | -57.56%703K | -45.84%783.32K | -23.64%1.3M |
Selling and administrative expenses | -13.64%2.95M | 19.74%849.5K | -3.77%676.52K | -16.12%657.01K | -37.09%769.43K | -42.23%3.42M | -48.13%709.47K | -55.99%703K | -43.64%783.25K | -21.74%1.22M |
-Selling and marketing expense | -94.03%16.32K | -83.67%2.69K | -97.91%450 | -88.35%3.86K | -95.39%9.32K | -76.39%273.41K | -94.38%16.44K | -92.92%21.55K | -89.31%33.09K | -19.40%202.32K |
-General and administrative expense | -6.65%2.94M | 22.19%846.82K | -0.79%676.07K | -12.93%653.15K | -25.53%760.11K | -33.92%3.15M | -35.55%693.02K | -47.29%681.45K | -30.55%750.16K | -22.19%1.02M |
Research and development costs | --0 | --0 | --0 | --0 | --0 | -76.10%76.49K | --0 | --0 | -99.87%74 | -44.99%76.41K |
Operating profit | -7.41%-3.17M | -2.92%-1.02M | 7.48%-746.67K | 32.28%-477.21K | -107.06%-923.81K | 42.01%-2.95M | 22.38%-995.29K | 23.80%-807.06K | 38.20%-704.63K | 72.31%-446.16K |
Net non-operating interest income expense | -22.70%26.14K | -25.91%5.76K | -22.06%6.27K | -23.09%6.91K | -20.11%7.21K | -4.24%33.82K | -27.54%7.77K | -25.01%8.04K | -15.29%8.98K | 176.69%9.02K |
Total other finance cost | 22.70%-26.14K | 25.91%-5.76K | 22.06%-6.27K | 23.09%-6.91K | 20.11%-7.21K | 4.24%-33.82K | 27.54%-7.77K | 25.01%-8.04K | 15.29%-8.98K | -176.69%-9.02K |
Other net income (expense) | 101.77%7.78K | 0 | 100.33%2.07K | -96.92%5.7K | ||||||
Other non- operating income (expenses) | ---- | ---- | ---- | ---- | ---- | -95.94%7.78K | --0 | ---- | --2.07K | -96.92%5.7K |
Income before tax | -8.05%-3.15M | -3.15%-1.02M | 7.34%-740.4K | 32.19%-470.3K | -112.45%-916.6K | 47.04%-2.91M | 22.34%-987.52K | 23.32%-799.02K | 60.61%-693.58K | 69.68%-431.44K |
Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income | -8.05%-3.15M | -3.15%-1.02M | 7.34%-740.4K | 32.19%-470.3K | -112.45%-916.6K | 47.04%-2.91M | 22.34%-987.52K | 23.32%-799.02K | 60.61%-693.58K | 69.68%-431.44K |
Net income continuous Operations | -8.05%-3.15M | -3.15%-1.02M | 7.34%-740.4K | 32.19%-470.3K | -112.45%-916.6K | 47.04%-2.91M | 22.34%-987.52K | 23.32%-799.02K | 60.61%-693.58K | 69.68%-431.44K |
Minority interest income | ||||||||||
Net income attributable to the parent company | -8.05%-3.15M | -3.15%-1.02M | 7.34%-740.4K | 32.19%-470.3K | -112.45%-916.6K | 47.04%-2.91M | 22.34%-987.52K | 23.32%-799.02K | 60.61%-693.58K | 69.68%-431.44K |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -8.05%-3.15M | -3.15%-1.02M | 7.34%-740.4K | 32.19%-470.3K | -112.45%-916.6K | 51.26%-2.91M | 22.34%-987.52K | 23.32%-799.02K | 60.61%-693.58K | 77.28%-431.44K |
Basic earnings per share | 2.54%-4.22 | 11.56%-1.3 | 21.01%-0.94 | 35.92%-0.66 | -120.00%-1.32 | 57.04%-4.33 | 18.33%-1.47 | 23.72%-1.19 | 62.68%-1.03 | 87.80%-0.6 |
Diluted earnings per share | 2.54%-4.22 | 11.56%-1.3 | 21.01%-0.94 | 35.92%-0.66 | -120.00%-1.32 | 57.04%-4.33 | 18.33%-1.47 | 23.72%-1.19 | 62.68%-1.03 | 87.80%-0.6 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |